Recent Publications by our Gynecologic Oncology Faculty
Peer Reviewed Publications
Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES.Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27. PMID: 31352365
Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.Gynecol Oncol. 2019 Aug;154(2):432-440. doi: 10.1016/j.ygyno.2019.05.022. Epub 2019 Jun 6. PMID: 31178149
Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786Kim JS, Ward KK, Shah NS, Saenz CC, McHale MT, Plaxe SC. Effects of obesity and hysterectomy approach on the surgical management of uterine malignancy. Am J Clin Exp Obstet Gynecol 2015;2(3):96-101.
Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES.Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27. PMID: 31352365
Lengmang S, Shephard S, Datta A, Lozo S, Kirschner CV.
Pubovesical sling for residual incontinence after successful vesicovaginal fistula closure: a new approach to an old procedure.
Int Urogynecol J. 2018 Oct;29(10):1551-1556. doi: 10.1007/s00192-018-3582-x. Epub 2018 Feb 21
PMID: 29468331Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786Shephard SN, Lengmang SJ, Anzaku SA, Mamven OV, Kirschner CV.
Effect of HIV infection on outcomes after surgical repair of genital fistula.
Int J Gynaecol Obstet. 2017 Sep;138(3):293-298. doi: 10.1002/ijgo.12233. Epub 2017 Jun 28
PMID 28602050 .Shephard SN, Lengmang SJ, Kirschner CV Bladder stones in vesicovaginal fistula: is concurrent repair an option? Experience with 87 patients. Int Urogynecol J. 2017 Apr;28(4):569-574. doi: 10.1007/s00192-016-3142-1. Epub 2016 Sep 17. PMID: 27640063
Kirschner CV, Lengmang SJ, Zhou Y, Chima GA, Karshima JA, Arrowsmith S. Urinary diversion for patients with inoperable obstetric vesicovaginal fistula: the Jos, Nigeria experience. Int Urogynecol J. 2016 Jun;27(6):865-70. doi: 10.1007/s00192-015-2871-x. Epub 2015 Nov 2. PMID:26527458
Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9.
Peterson CE, Rauscher GH, Johnson TP, Kirschner CV, Freels S, Barrett RE, Kim S, Fitzgibbon ML, Joslin CE, Davis FG.The effect of neighborhood disadvantage on the racial disparity in ovarian cancer-specific survival in a large hospital-based study in cook county, illinois.Front Public Health. 2015 Jan 22;3:8
Kurnit KC, Avila M, Hinchcliff E, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions [published online ahead of print, 2020 May 22]. Pharmacol Ther. 2020;107588. doi:10.1016/j.pharmthera.2020.107588
Kurnit KC, Westin SN. Slow and steady wins the race: precision medicine for low risk endometrial cancer. Int J Gynecol Cancer. 2020;30(6):724-725. doi:10.1136/ijgc-2020-001467
Kurnit KC, Westin SN. Slow and steady wins the race: precision medicine for low risk endometrial cancer. Int J Gynecol Cancer. 2020;30(6):724-725. doi:10.1136/ijgc-2020-001467
Matsuo K, Cripe JC, Kurnit KC, et al. Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecol Oncol. 2019;155(1):39-50. doi:10.1016/j.ygyno.2019.08.007
Kurnit KC, Lu KH, Westin SN. Rapidly Changing Landscape of Fallopian Tube Carcinoma. J Oncol Pract. 2019;15(7):383-384. doi:10.1200/JOP.19.00248
Kurnit KC, Westin SN, Coleman RL. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer. 2019;125(13):2154-2163. doi:10.1002/cncr.32058
Kurnit KC, Previs RA, Soliman PT, et al. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019;152(1):31-37. doi:10.1016/j.ygyno.2018.10.034
Colombo I, Kurnit KC, Westin SN, Oza AM. Moving From Mutation to Actionability. Am Soc Clin Oncol Educ Book. 2018;38:495-503. doi:10.1200/EDBK_199665
Kim G, Kurnit KC, Djordjevic B, et al. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018;31(10):1553-1559. doi:10.1038/s41379-018-0080-0
Kurnit KC, Dumbrava EEI, Litzenburger B, et al. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res. 2018;24(12):2719-2731. doi:10.1158/1078-0432.CCR-17-2494
Kurnit KC, Bailey AM, Zeng J, et al. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. Cancer Res. 2017;77(21):e123-e126. doi:10.1158/0008-5472.CAN-17-0341
Kurnit KC, Kim GN, Fellman BM, et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017;30(7):1032-1041. doi:10.1038/modpathol.2017.15
Kurnit KC, Bean LM, Plaxe SC, Saenz CC, McHale MT. Squamous Cell Carcinoma of the Vulva Presenting as an Isolated Inguinal Lymph Node Metastasis: A Case Report. J Reprod Med. 2016;61(11-12):612-614.
Kurnit KC, Overcash RT, Ramos GA, LaCoursiere DY. The impact of inadequate gestational weight gain in obese diabetic women. J Perinatol. 2016;36(2):86-89. doi:10.1038/jp.2015.155
Kurnit KC, Ward KK, McHale MT, Saenz CC, Plaxe SC. Increased prevalence of comorbid conditions in women with uterine cancer. Gynecol Oncol. 2015;138(3):731-734. doi:10.1016/j.ygyno.2015.07.004
Farley JH, Hines J, Lee NK, et al. Promoting health equity in the era of COVID-19. Gynecol Oncol. 2020;158(1):25-31. doi:10.1016/j.ygyno.2020.05.023
Hasan Y, Furtado L, Tergas A, et al. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020;107(3):487-498. doi:10.1016/j.ijrobp.2020.02.031
Hoppenot C, Hlubocky FJ, Chor J, Yamada SD, Lee NK. Approach to Palliative Care Consultation for Patients With Malignant Bowel Obstruction in Gynecologic Oncology: A Qualitative Analysis of Physician Perspectives [published online ahead of print, 2020 Apr 2]. JCO Oncol Pract. 2020;JOP1900710. doi:10.1200/JOP.19.00710
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Ann Surg Oncol. 2020;27(6):1798-1804. doi:10.1245/s10434-020-08323-x
Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer. 2020;126(11):2553-2560. doi:10.1002/cncr.32867
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer.CA Cancer J Clin. 2019 Jul;69(4):258-279. doi: 10.3322/caac.21561. Epub 2019 May 10. Review. PMID: 31074865
Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? Gynecol Oncol. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2. PMID: 31056111
Ross JGC, Escamilla V, Lee NK, Diane Yamada S, Lindau ST.Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.Gynecol Oncol. 2019 Feb;152(2):322-327. doi: 10.1016/j.ygyno.2018.12.005. Epub 2018 Dec 20. PMID: 30581035
Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786Feng CH, Miller CM, Tenney ME, Lee NK, Yamada SD, Hasan Y. Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 Nov;26(9):1642-1649. PMID: 27654261
Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9
Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr;137(1):119-24
Adeleye A, Lengyel E. Care of Transgender Persons. N Engl J Med. 2020;382(15):1481-1482. doi:10.1056/NEJMc2000825
Coscia F, Doll S, Bech JM, et al. A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. J Pathol. 2020;251(1):100-112. doi:10.1002/path.5420
Mukherjee A, Chiang CY, Daifotis HA, et al. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res. 2020;80(8):1748-1761. doi:10.1158/0008-5472.CAN-19-1999
Hart PC, Kenny HA, Grassl N, et al. Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019;29(12):4086-4098.e6. doi:10.1016/j.celrep.2019.11.079
Ko SY, Lee W, Kenny HA, et al. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019;2:386. Published 2019 Oct 18. doi:10.1038/s42003-019-0609-x
Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, Brimacombe KR, Marugan J, Ferrer M, Lengyel E. Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Mol Cancer Ther. 2020 Jan;19(1):52-62. doi: 10.1158/1535-7163.MCT-19-0052. Epub 2019 Sep 27. PMID: 31562255
Zhang Z, Zhan Q, Eckert M, Zhu A, Chryplewicz A, De Jesus DF, Ren D, Kulkarni RN, Lengyel E, He C, Chen M. RADAR: differential analysis of MeRIP-seq data with a random effect model. Genome Biol. 2019 Dec 23;20(1):294. doi: 10.1186/s13059-019-1915-9. PMID: 31870409
Hart PC, Kenny HA, Grassl N, Watters KM, Litchfield LM, Coscia F, Blaženović I, Ploetzky L, Fiehn O, Mann M, Lengyel E, Romero IL. Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 Dec 17;29(12):4086-4098.e6. doi: 10.1016/j.celrep.2019.11.079. PMID: 31851935
Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H.Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019 Oct 18;2(1):386. doi: 10.1038/s42003-019-0609-x. PMID: 31925178
Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H.Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019 Oct 18;2:386. doi: 10.1038/s42003-019-0609-x. eCollection 2019. PMID: 31646189
Li G, Eckert MA, Chang JW, Montgomery JE, Chryplewicz A, Lengyel E, Moellering RE. Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21493-21500. doi: 10.1073/pnas.1912934116. Epub 2019 Oct 7. PMID: 31591248
Dauer P, Lengyel E. New Roles for Glycogen in Tumor Progression. Trends Cancer. 2019 Jul;5(7):396-399. doi: 10.1016/j.trecan.2019.05.003. Epub 2019 May 31. PMID: 31311654
…Lavarone C, Lengyel ER…,Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5. PMID: 30835824
McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, Huang XY, Lengyel E, Kenny HA.Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 2019 May;153(2):405-415. doi: 10.1016/j.ygyno.2019.01.020. Epub 2019 Feb 20. PMID: 30797592
Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 May;569(7758):723-728. doi: 10.1038/s41586-019-1173-8. Epub 2019 May 1. PMID: 31043742
Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, Loth R, Lastra R, McGregor SM, Locasale JW, Lengyel E, Romero IL. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 Apr;17(4):870-881. doi: 10.1158/1541-7786.MCR-18-0409. Epub 2019 Jan 17. PMID: 30655321
Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep. 2019 Mar 26;9(1):5195. doi: 10.1038/s41598-019-41352-5. PMID: 30914657
Chapel DB, Lengyel E, Ritterhouse LL, Lastra RR. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Int J Gynecol Pathol. 2019 Feb 21. doi: 10.1097/PGP.0000000000000594. [Epub ahead of print] PMID: 30807370
Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 Jan 7;216(1):176-194. doi: 10.1084/jem.20181170. Epub 2018 Dec 19. PMID: 30567719
Javellana M, Hoppenot C, Lengyel E
The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404-5. doi: 10.1016/j.ygyno.2018.11.007. [Epub ahead of print]
PMID: 30471899Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DW.
A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.
Biomaterials. 2018 Oct 16;190-191:63-75. doi: 10.1016/j.biomaterials.2018.10.014. [Epub ahead of print]
PMID:30396040Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M.
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
PMID:30241606Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E.
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Cell Metab. 2018 Aug 28. pii: S1550-4131(18)30508-4. doi: 10.1016/j.cmet.2018.08.007. [Epub ahead of print]
PMID: 30174305Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He C.
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.
Nat Cell Biol. 2018 Sep;20(9):1074-1083. doi: 10.1038/s41556-018-0174-4. Epub 2018 Aug 27.
PMID: 30154548Curtis M, Mukherjee A, Lengyel E.
The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis.
Trends Cancer. 2018 Aug;4(8):517-519. doi: 10.1016/j.trecan.2018.06.002. Epub 2018 Jun 22.
PMID: 30064659
.
Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Clin Cancer Res. 2018 Nov 1;24(21):5357-5367. doi: 10.1158/1078-0432.CCR-18-0142. Epub 2018 May 2.
PMID: 29720506Lengyel E, Makowski L, DiGiovanni J, Kolonin MG
Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors.
Trends Cancer. 2018 May;4(5):374-384. doi: 10.1016/j.trecan.2018.03.004. Epub 2018 Apr 5. Review.
PMID:29709261
Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E.
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
Oncogene. 2018 Apr;37(17):2285-2301. doi: 10.1038/s41388-017-0093-z. Epub 2018 Feb 5.
PMID:29398710Li G, Montgomery JE, Eckert MA, Chang JW, Tienda SM, Lengyel E, Moellering RE
An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells.
Nat Commun. 2017 Nov 24;8(1):1775. doi: 10.1038/s41467-017-01854-0.
PMID:29176560Hoppenot C, Eckert MA, Tienda SM, Lengyel E.
Who are the long-term survivors of high grade serous ovarian cancer?
Gynecol Oncol. 2018 Jan;148(1):204-212. doi: 10.1016/j.ygyno.2017.10.032. Epub 2017 Nov 8. Review.
PMID: 29128106Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
Gynecol Oncol. 2017 Jul;146(1):153-160. doi: 10.1016/j.ygyno.2017.04.012. Epub 2017 Apr 26.
PMID:28456378Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M
A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth.
SLAS Discov. 2017 Jun;22(5):494-506. doi: 10.1177/2472555216687082. Epub 2017 Jan 31Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF.High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30793-X. . [Epub ahead of print] PMID:28456378
Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M.A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 Jun;22(5):494-506. doi: 10.1177/2472555216687082. Epub 2017 Jan 31. PMID: 28346091
Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero ILLoss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. . Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. Epub 2017 Mar 6.
PMID: 28264838Mukherjee A, Kenny HA, Lengyel E Unsaturated Fatty Acids Maintain Cancer Cell Stemness.
Cell Stem Cell. 2017 Mar 2;20(3):291-292. doi: 10.1016/j.stem.2017.02.008. PMID: 28257705Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E Piccirilli JA Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 Apr ;77(7):1684-1696. Epub 2017 Feb 15. PMID: 28202518
Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 Dec;6(12):1342-1351. Epub 2016 Oct 7. PMID: 27856443
Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, Lengyel E, Kimura T Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells.
Mol Cancer Res. 2017 Jan;15(1):78-92.. Epub 2016 Oct 6. PMID: 27758876Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
Cell Metab. 2016 Nov 8;24(5):728-739. Epub 2016 Oct 13. PMID: 27746051Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat Commun. 2016 Aug 26;7:12645. doi: 10.1038/ncomms12645. PMID: 27561551Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 Oct;15(10):2282-2293. Epub 2016 Jul 27. PMID: 27466355
Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD.A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 Jul;142(1):169-75. doi: 10.1016/j.ygyno.2016.04.018. Epub 2016 Apr 28. PMID: 27103176
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: .1038/nrc4019. Review. PMID: 26493647
Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero ILHyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15;6(27):23548-60. PMID: 26172303
Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep;138(3):656-62. Epub 2015 Jun 24. PMID: 26115975
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, NonesK, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, HarliwongI, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 521(7553), 489-94. PMID: 26017449.
Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecologic Oncology, 2015, 137(3):485-9, PMID 25838164
Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T. The hypoxia-related microRNA-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget, 2015, 6(13), 11342-56. PMID: 25839163
Kohlhapp F, Mitra AK, Lengyel E, Peter ME microRNAs as mediators and communicators between cancer cells and the tumor micro-environment. Oncogene, 2015, in press
PMID 25867073Mitra AK, Chiang CY, Tiwari P, Watters KM, Peter ME, and Lengyel E Microenvironment induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene, 2015, in press PMID 25798837
Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee WS, Romero I Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. American Journal of Obstetrics and Gynecology, 2015, 212(4):479.e1-479.e10. PMCID: PMC4387077
King M, Lindberg M, Stodden G, Okuda H, Ebers S, Johnson A, Montag A, Lengyel E, MacLean J, Hayashi K. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer, Oncogene, 2015, 34(26):3452-62. PMID 25174399
Romero IL, Mukherjee A, Kenny HA, Litchfield LM, and Lengyel E. Molecular Pathways: Trafficking of metabolic resources in the tumor microenvironment. Clinical Cancer Research, 2015, 21 (4): 680-686. PMID 25691772
Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, and Lengyel E. Quantitive high throughput screening (HTS) using a physiologically-relevant primary human three-dimensional organotypic culture predicts in vivo efficacy. Nature Communications, 2015, 6:6220. PMID 25653139
Mills KA, Joshi TV, West L, et al. Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?. Gynecol Oncol. 2020;157(3):706-710. doi:10.1016/j.ygyno.2020.02.033
Gillen J, Mills KA, Dvorak J, et al. Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab. Gynecol Oncol Rep. 2019;30:100502. Published 2019 Oct 5. doi:10.1016/j.gore.2019.100502
Mills KA, Lopez H, Sun L, et al. Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?. Gynecol Oncol Rep. 2019;29:20-24. Published 2019 May 23. doi:10.1016/j.gore.2019.05.007
Mills KA, Lopez H, Sun L, et al. Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?. Gynecol Oncol Rep. 2019;29:20-24. Published 2019 May 23. doi:10.1016/j.gore.2019.05.007
Mills KA, Quinn JM, Roach ST, et al. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. Sci Rep. 2019;9(1):4762. Published 2019 Mar 18. doi:10.1038/s41598-019-41122-3
Cripe JC, Buchanan TR Jr, Kuroki LM, et al. Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer. Gynecol Oncol. 2019;153(1):123-126. doi:10.1016/j.ygyno.2019.01.009
Mills KA, Roach ST, Quinn JM, et al. SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. Gynecol Oncol. 2018;151(2):337-344. doi:10.1016/j.ygyno.2018.08.008
Cripe JC, Mills KA, Kuroki LK, et al. Gynecologic Oncologists' Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology. Gynecol Obstet Invest. 2019;84(1):50-55. doi:10.1159/000491089
Kim JS, Mills KA, Fehniger J, et al. Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer. Int J Gynecol Cancer. 2017;27(8):1774-1782. doi:10.1097/IGC.0000000000001084
Ezewuiro O, Grushko TA, Kocherginsky M, et al. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS One. 2016;11(1):e0147145. Published 2016 Jan 20. doi:10.1371/journal.pone.0147145
Litchfield LM, Mukherjee A, Eckert MA, et al. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015;6(27):23548-23560. doi:10.18632/oncotarget.4556
Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES.Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27. PMID: 31352365
Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?Gynecol Oncol. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2. PMID: 31056111
Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM Jr, Gunderson CC, Moore KN, Erickson BK, Leath CA 3rd, Diaz Moore ES, Cohen JG, Walsh CS.Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.Gynecol Oncol. 2017 Feb;144(2):274-278. doi: 10.1016/j.ygyno.2016.12.004. Epub 2016 Dec 12. PMID: 27979319Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782 PMID:28708786Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer.CA Cancer J Clin. 2019 Jul;69(4):258-279. doi: 10.3322/caac.21561. Epub 2019 May 10. Review. PMID: 31074865
Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print] PMID: 31194228
Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13. PMID: 29437535
Luke AM, Moroney JW, Snitchler A, Whiteway SL. Ovarian Sertoli-Leydig Cell Tumor with Elevated Inhibin B as a Cause of Secondary Amenorrhea in an Adolescent with Germ Line DICER1 Mutation. J Pediatr Adolesc Gynecol. 2017 Oct;30(5):598-600. doi: 10.1016/j.jpag.2017.05.002. Epub 2017 May 11. PMID: 28502826
Son CH, Fleming GF, Moroney JW.
Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.
Cancer Manag Res. 2017 Oct 31;9:553-563. doi: 10.2147/CMAR.S116683. eCollection 2017. Review.
PMID:29184441Luke AM, Moroney JW, Snitchler A, Whiteway SL .Recurrent ovarian Sertoli-Leydig cell tumor; a rare cause of secondary amenorrhea in adolescence.
J Pediatr Adolesc Gynecol. 2017 May 11. pii: S1083-3188(16)30285-6. [Epub ahead of print]
PMID:28502826Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R.Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Ann Oncol. 2015 Jul;26(7):1346-52.. Epub 2015 Apr 15.
PMID:25878190Millstein J, Budden T, Goode EL, et al. Prognostic gene expression signature for high-grade serous ovarian cancer [published online ahead of print, 2020 May 27]. Ann Oncol. 2020;S0923-7534(20)39841-0. doi:10.1016/j.annonc.2020.05.019
Rodriguez GC, Kauderer J, Hunn J, et al. Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. Cancer Prev Res (Phila). 2019;12(6):401-412. doi:10.1158/1940-6207.CAPR-18-0383
Lu Y, Beeghly-Fadiel A, Wu L, et al. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018;78(18):5419-5430. doi:10.1158/0008-5472.CAN-18-0951
Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML.Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 Jan;156(1):131-139. doi: 10.1016/j.ygyno.2019.10.026. Epub 2019 Nov 21. PMID: 31759774
Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ, Brooks RA, Cass I, Cohen JG, Penner KR, Wang CE, Diaz Moore ES. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27. PMID: 31352365
Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019 Aug;154(2):432-440. doi: 10.1016/j.ygyno.2019.05.022. Epub 2019 Jun 6. PMID: 31178149
...Robson M, Rodriguez GC…Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 Jul;121(2):180-192. doi: 10.1038/s41416-019-0492-8. Epub 2019 Jun 19. PMID: 31213659
Rodriguez GC, Kauderer J, Hunn J, Thaete LG, Watkin WG, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS.Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study.Cancer Prev Res (Phila). 2019 Jun;12(6):401-412. doi: 10.1158/1940-6207.CAPR-18-0383. Epub 2019 Apr 23. PMID: 31015198
… Robson M, Rodriguez GC….
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
J Natl Cancer Inst. 2018 Oct 12. [Epub ahead of print]
PMID:30312457…Rennert G, Risch H, Rodriguez GC…
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.
Cancer Res. 2018 Sep 15;78(18):5419-5430.. Epub 2018 Jul 27.
PMID:30054336…Rhiem K, Robson M, Rodriguez GC…
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Hum Mutat. 2018 May;39(5):593-620.. Epub 2018 Mar 12.
PMID:29446198Waheed S, Dorjbal B, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V.
Progesterone and calcitriol reduce invasive potential of endometrial cancer cells by targeting ARF6, NEDD9 and MT1-MMP.
Oncotarget. 2017 Nov 28;8(69):113583-113597. eCollection 2017 Dec 26.
PMID:29371931
….Rhiem K, Richardson A, Rodriguez GC, ….
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.
Nat Genet. 2017 Dec;49(12):1767-1778 Epub 2017 Oct 23.
PMID:29058716Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786Phelan CM, Kuchenbaecker KB…Rodriguez GC Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Nat Genet. 2017 May;49(5):680-691. Epub 2017 Mar 27.
PMID: 28346442Hamdi Y, Soucy P, Kuchenbaeker KB…Rodriguez GC
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Breast Cancer Res Treat. 2017 Jan;161(1):117-134. Epub 2016 Oct 28.
PMID: 27796716Hibler EA, Kauderer J, Greene MH, Rodriguez GC, Alberts DS.
Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.
Menopause. 2016 Nov;23(11):1228-1232.
PMID:27433858Bokhari AA, Lee LR, Raboteau D, Turbov J, Rodriguez IV, Pike JW, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V.
Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1.
Oncotarget. 2016 Nov 22;7(47):77576-77590.
PMID:27769055Lawrenson K, Kar S, McCue K, Kuchenbaeker K…Rodriguez G,
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Nat Commun. 2016 Sep 7;7:12675.
PMID:27601076Vigorito E, Kuchenbaecker KB... Rodriguez GC
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
PLoS One. 2016 Jul 27;11(7):e0158801. eCollection 2016.
PMID: 27463617Rodriguez GC, Turbov J, Rosales R, Yoo J, Hunn J, Zappia KJ, Lund K, Barry CP, Rodriguez IV, Pike JW, Conrads TP, Darcy KM, Maxwell GL, Hamilton CA, Syed V, Thaete LG.
Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.
Gynecol Oncol. 2016 Oct;143(1):159-67. Epub 2016 Jul 29.
PMID: 27106018Rebbeck TR, Mitra N, Wan F, Sinilnikova…., Rodriguez G,.et. al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 7;313(13):1347-61
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (multiple authors) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2015 May 2
Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9.
Blanco I, Kuchenbaecker K and multiple authors. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.PLoS One. 2015 Apr 1;10(4):e0120020
Blanco I, Kuchenbaecker K and multiple authors. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb;47(2):164-71
Peterlongo P and multiple authors. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16
Kim JS, Liang MI, Prendergast EN, et al. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. Int J Gynecol Cancer. 2019;29(7):1156-1163. doi:10.1136/ijgc-2019-000374
Vogel TJ, Goodman MT, Li AJ, Jeon CY. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecol Oncol. 2017;146(2):340-345. doi:10.1016/j.ygyno.2017.05.009
Vogel TJ, Jeon C, Karlan B, Walsh C. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. Gynecol Oncol. 2016;140(2):285-288. doi:10.1016/j.ygyno.2015.12.003
Vogel TJ, Knickerbocker A, Shah CA, et al. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. J Gynecol Oncol. 2015;26(1):25-31. doi:10.3802/jgo.2015.26.1.25
Yucer N, Holzapfel M, Jenkins Vogel T, Lenaeus L, Ornelas L, Laury A, Sareen D, Barrett R, Karlan BY, Svendsen CN. Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium. Sci Rep. 2017 Sep 6;7(1):10741. doi: 10.1038/s41598-017-05519-2. PMID: 28878359
Vogel TJ, Goodman MT, Li AJ, Jeon CY
Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Gynecol Oncol. 2017 Aug;146(2):340-345. doi: 10.1016/j.ygyno.2017.05.009. Epub 2017 Jun 7.
PMID:28596017Vogel TJ, Jeon C, Karlan B, Walsh C. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. Gynecol Oncol. 2016 Feb;140(2):285-8. doi: 10.1016/j.ygyno.2015.12.003. PubMed PMID: 26691221
Vogel TJ, Knickerbocker A, Shah CA, Schiff MA, Isacson C, Garcia RL, Goff BA. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers. J Gynecol Oncol. 2015 Jan;26(1):25-31. doi: 10.3802/jgo.2015.26.1.25. PubMed PMID: 25376917; PubMed Central PMCID: PMC4302281
Laibangyang A, Alter R, Hasan Y, Yamada SD. Superior vena cava syndrome associated with uterine serous carcinoma. Gynecol Oncol Rep. 2020;33:100593. Published 2020 May 30. doi:10.1016/j.gore.2020.100593
Fader AN, Huh WK, Kesterson J, et al. When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic [published online ahead of print, 2020 Jun 6]. Gynecol Oncol. 2020;S0090-8258(20)31766-2. doi:10.1016/j.ygyno.2020.06.001
Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Ann Surg Oncol. 2020;27(6):1780-1787. doi:10.1245/s10434-020-08322-y
Hoppenot C, Hlubocky FJ, Chor J, Yamada SD, Lee NK. Approach to Palliative Care Consultation for Patients With Malignant Bowel Obstruction in Gynecologic Oncology: A Qualitative Analysis of Physician Perspectives [published online ahead of print, 2020 Apr 2]. JCO Oncol Pract. 2020;JOP1900710. doi:10.1200/JOP.19.00710
Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?Gynecol Oncol. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2. PMID: 31056111
Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.Nature. 2019 May;569(7758):723-728. doi: 10.1038/s41586-019-1173-8. Epub 2019 May 1. PMID: 31043742
Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.Ross JGC, Escamilla V, Lee NK, Diane Yamada S, Lindau ST.Gynecol Oncol. 2019 Feb;152(2):322-327. doi: 10.1016/j.ygyno.2018.12.005. Epub 2018 Dec 20. PMID: 30581035
Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
PMID:30241606Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E.
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Cell Metab. 2018 Aug 28. pii: S1550-4131(18)30508-4. [Epub ahead of print]
PMID:30174305Cowan M, Suntum T, Olivas AD, Perpich M, Applebaum MA, Lastra RR, Yamada SD.
Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome.
Gynecol Oncol Rep. 2018 Jun 15;25:94-97. eCollection 2018 Aug.
PMID:30014022Chapel DB, Yamada SD, Cowan M, Lastra RR.
Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Gynecol Oncol. 2018 Jun;149(3):570-574. doi: 10.1016/j.ygyno.2018.04.005. Epub 2018 Apr 13.
PMID:29656794Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E.
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
Oncogene. 2018 Apr;37(17):2285-2301.. Epub 2018 Feb 5.
PMID 29398710Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.
Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782
PMID:28708786Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6. PMID: 28264838
Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 Dec;6(12):1342-1351. Epub 2016 Oct 7. PMID: 27856443
Feng CH, Miller CM, Tenney ME, Lee NK, Yamada SD, Hasan Y.Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 Nov;26(9):1642-1649. PMID:27654261
Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD.A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 Jul;142(1):169-75. doi: 10.1016/j.ygyno.2016.04.018. Epub 2016 Apr 28. PMID:27103176
He C, Poon C, Chan C, Yamada SD, Lin W. Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer. J Am Chem Soc. 2016 May 11;138(18):6010-9. doi: 10.1021/jacs.6b02486. Epub 2016 May 2. PMID:27088560
He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin W Nanomedicine for Combination Therapy of Cancer. EBioMedicine. 2015 May 13;2(5):366-7. doi: 10.1016/j.ebiom.2015.05.013. eCollection 2015 May. No abstract available.
PMID:26137577He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin W. Nanomedicine for Combination Therapy of Cancer.EBioMedicine. 2015 May 13;2(5):366-7
Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun;137(3):485-9
Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr;137(1):119-24
Bennett JA, Costa Braga A, Pinto A, Van de Vijver K, Cornejo K, Pesci A, Zhang L, Morales-Oyarvide V, Kiyokawa T, Zannoni GF, Carlson J, Slavik T, Tornos C, Antonescu CR, Oliva E. Uterine PEComas: A Morphological, Immunohistochemical, and Molecular Analysis of 32 Tumors. Am J Surg Path. 2018; 42: 1370-1383.
Bennett JA, Young RH, Chuang A, Lerwill MF. Ovarian Metastases of Breast Cancers with Signet Ring Cells: A Report of 17 Cases Including 14 Krukenberg Tumors. Int J Gynecol Pathol. 2018; 37: 507-515.
Bennett JA, Pesci A, Morales-Oyarvide V, Da Silva A, Nardi V, Oliva E. Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas. Am J Surg Pathol. 2019; 43: 229-234.
Bennett JA, Ritterhouse LL, Furtado LV, Lastra RR, Pesci A, Newell JM, Burandt E, Kooreman L, Van de Vijver K, Krausz T, Felix A, Zannoni GF, Young RH, Oliva E. Female Adnexal Tumors of Probable Wolffian Origin: Morphological, Immunohistochemical, and Molecular Analysis of 15 Cases. Mod Pathol. 2020; 33: 734-747.
Bennett JA, Croce S, Pesci A, Niu N, Van de Vijver K, Burks EJ, Burandt E, Zannoni GF, Rabban JT, Oliva E. Inflammatory Myofibroblastic Tumor of the Uterus: An Immunohistochemical Study of 24 Cases. Am J Surg Pathol. 2020; 44: 1441-1449.
Bennett JA, Lastra RR, Barroeta J, Parilla M, Galbo F, Wanjari P, Young RH, Krausz T, Oliva E. Uterine Tumor Resembling Ovarian Sex Cord Stromal Tumor (UTROSCT): A Series of 3 Cases with Extensive Rhabdoid Differentiation, Malignant Behavior, and ESR1-NCOA2 Fusions. Am J Surg Pathol. 2020; 44: 1563-1572.
Sharma AE, Hamedani FS, Barroeta JE, Pytel P, Bennett JA, Lastra RR. Clear Cell Papillary Cystadenoma of the Ovary Masquerading as Metastatic Clear Cell Renal Cell Carcinoma: A Case Report and Review of the Literature. Int J Gynecol Pathol. 2020 Jan 23. [Epub ahead of print].
Bennett JA, Safdar N, Segal JP, Lastra RR, Oliva E. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma. Int J Gynecol Pathol. 2020 Sep 4. [Epub ahead of print].